Evidence map›Paper›PMID 34632664›Full record

ArticleCancer science2021

Crucial contribution of GPR56/ADGRG1, expressed by breast cancer cells, to bone metastasis formation.

So-Ichiro Sasaki, Di Zhang, Sadahiro Iwabuchi, Yamato Tanabe, Shinichi Hashimoto, Akira Yamauchi, Katsuhiro Hayashi, Hiroyuki Tsuchiya, Yoshihiro Hayakawa, Tomohisa Baba and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Alternative splicing of transposable elements in human breast cancer.bioRxiv : the preprint server for biology · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

So-Ichiro SasakiCancer Research Institute, Division of Molecular Bioregulation, Kanazawa University, Ishikawa, Japan.ORCID https://orcid.org/0000-0001-9092-7181
Di ZhangCancer Research Institute, Division of Molecular Bioregulation, Kanazawa University, Ishikawa, Japan.
Sadahiro IwabuchiInstitute of Advanced Medicine, Department of Molecular Pathophysiology, Wakayama Medical University, Wakayama, Japan.
Yamato TanabeCancer Research Institute, Division of Molecular Bioregulation, Kanazawa University, Ishikawa, Japan.
Shinichi HashimotoInstitute of Advanced Medicine, Department of Molecular Pathophysiology, Wakayama Medical University, Wakayama, Japan.
Akira YamauchiTazuke Kofukai Medical Research Institute, Department of Breast Surgery, Osaka, Japan.
Katsuhiro HayashiDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
Hiroyuki TsuchiyaDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
Yoshihiro HayakawaSection of Host Defences, Institute of Natural Medicine, University of Toyama, Toyama, Japan.ORCID https://orcid.org/0000-0002-7921-1171
Tomohisa BabaCancer Research Institute, Division of Molecular Bioregulation, Kanazawa University, Ishikawa, Japan.
Naofumi MukaidaCancer Research Institute, Division of Molecular Bioregulation, Kanazawa University, Ishikawa, Japan.
Kanazawa University · JPWakayama Medical University · JPKitano Hospital · JPUniversity of Toyama · JP

Funding

Japan Society for the Promotion of Science (JSPS) KAKENHI 17k07159
6 · The paper itself

Abstract

From a mouse triple-negative breast cancer cell line, 4T1, we previously established 4T1.3 clone with a high capacity to metastasize to bone after its orthotopic injection into mammary fat pad of immunocompetent mice. Subsequent analysis demonstrated that the interaction between cancer cells and fibroblasts in a bone cavity was crucial for bone metastasis focus formation arising from orthotopic injection of 4T1.3 cells. Here, we demonstrated that a member of the adhesion G-protein-coupled receptor (ADGR) family, G-protein-coupled receptor 56 (GPR56)/adhesion G-protein-coupled receptor G1 (ADGRG1), was expressed selectively in 4T1.3 grown in a bone cavity but not under in vitro conditions. Moreover, fibroblasts present in bone metastasis sites expressed type III collagen, a ligand for GPR56/ADGRG1. Consistently, GPR56/ADGRG1 proteins were detected in tumor cells in bone metastasis foci of human breast cancer patients. Deletion of GPR56/ADGRG1 from 4T1.3 cells reduced markedly intraosseous tumor formation upon their intraosseous injection. Conversely, intraosseous injection of GPR56/ADGRG1-transduced 4T1, TS/A (mouse breast cancer cell line), or MDA-MB-231 (human breast cancer cell line) exhibited enhanced intraosseous tumor formation. Furthermore, we proved that the cleavage at the extracellular region was indispensable for GPR56/ADGRG1-induced increase in breast cancer cell growth upon its intraosseous injection. Finally, inducible suppression of Gpr56/Adgrg1 gene expression in 4T1.3 cells attenuated bone metastasis formation with few effects on primary tumor formation in the spontaneous breast cancer bone metastasis model. Altogether, GPR56/ADGRG1 can be a novel target molecule to develop a strategy to prevent and/or treat breast cancer metastasis to bone.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsBone NeoplasmsCell Line, TumorCell ProliferationCollagen Type IIIFemaleGene DeletionHumansMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CMice, SCIDProtein BindingReceptors, G-Protein-CoupledTumor BurdenAdgrg1 protein, mouseCollagen Type IIIReceptors, G-Protein-Coupledbone metastasisfibroblastGPR56/ADGRG1mousetriple-negative breast cancer

Identifiers

PMID34632664
PMCPMC8645723
OpenAlexW3207770326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.